Zura Bio (ZURA) to Release Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Friday, November 14, 2025 at 9:30 AM ET.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Stock Down 4.2%

NASDAQ ZURA opened at $3.68 on Tuesday. Zura Bio has a 52-week low of $0.97 and a 52-week high of $4.85. The business’s 50-day moving average price is $2.96 and its 200 day moving average price is $1.91. The firm has a market cap of $239.27 million, a P/E ratio of -5.26 and a beta of 0.24.

Institutional Investors Weigh In On Zura Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC acquired a new stake in shares of Zura Bio during the 1st quarter valued at approximately $72,000. Bank of America Corp DE raised its position in shares of Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Zura Bio during the 2nd quarter worth approximately $113,000. Finally, JPMorgan Chase & Co. raised its position in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after purchasing an additional 2,052,732 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ZURA shares. HC Wainwright lowered their price target on Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Tuesday, October 14th. Oppenheimer lowered their price target on Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, August 15th. Finally, Chardan Capital reissued a “buy” rating and set a $10.00 price target on shares of Zura Bio in a report on Tuesday, September 30th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.75.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.